Author: Mahevas, Matthieu; Tran, Viet-Thi; Roumier, Mathilde; Chabrol, Amelie; Paule, Romain; Guillaud, Constance; Gallien, Sebastien; Lepeule, Raphael; Szwebel, Tali-Anne; Lescure, Xavier; Schlemmer, Frederic; Matignon, Marie; Khellaf, Mehdi; Crickx, Etienne; Terrier, Benjamin; Morbieu, Caroline; Legendre, Paul; Dang, Julien; Schoindre, Yoland; Pawlotski, Jean-Michel; Michel, Marc; Perrodeau, Elodie; Carlier, Nicolas; Roche, Nicolas; De Lastours, Victoire; Mouthon, Luc; Audureau, Etienne; Ravaud, Philippe; Godeau, Bertrand; Costedoat, Nathalie
Title: No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial Cord-id: otp1atui Document date: 2020_4_14
ID: otp1atui
Snippet: Background Treatments are urgently needed to prevent respiratory failure and deaths from coronavirus disease 2019 (COVID-19). Hydroxychloroquine (HCQ) has received worldwide attention because of positive results from small studies. Methods We used data collected from routine care of all adults in 4 French hospitals with documented SARS-CoV-2 pneumonia and requiring oxygen ≥ 2 L/min to emulate a target trial aimed at assessing the effectiveness of HCQ at 600 mg/day. The composite primary endpoi
Document: Background Treatments are urgently needed to prevent respiratory failure and deaths from coronavirus disease 2019 (COVID-19). Hydroxychloroquine (HCQ) has received worldwide attention because of positive results from small studies. Methods We used data collected from routine care of all adults in 4 French hospitals with documented SARS-CoV-2 pneumonia and requiring oxygen ≥ 2 L/min to emulate a target trial aimed at assessing the effectiveness of HCQ at 600 mg/day. The composite primary endpoint was transfer to intensive care unit (ICU) within 7 days from inclusion and/or death from any cause. Analyses were adjusted for confounding factors by inverse probability of treatment weighting. Results This study included 181 patients with SARS-CoV-2 pneumonia; 84 received HCQ within 48 hours of admission (HCQ group) and 97 did not (no-HCQ group). Initial severity was well balanced between the groups. In the weighted analysis, 20.2% patients in the HCQ group were transferred to the ICU or died within 7 days vs 22.1% in the no-HCQ group (16 vs 21 events, relative risk [RR] 0.91, 95% CI 0.47-1.80). In the HCQ group, 2.8% of the patients died within 7 days vs 4.6% in the no-HCQ group (3 vs 4 events, RR 0.61, 95% CI 0.13-2.89), and 27.4% and 24.1%, respectively, developed acute respiratory distress syndrome within 7 days (24 vs 23 events, RR 1.14, 95% CI 0.65-2.00). Eight patients receiving HCQ (9.5%) experienced electrocardiogram modifications requiring HCQ discontinuation. Interpretation These results do not support the use of HCQ in patients hospitalised for documented SARS-CoV-2-positive hypoxic pneumonia.
Search related documents:
Co phrase search for related documents- active therapeutic and logistic regression: 1
- acute ards respiratory distress syndrome and liver cirrhosis: 1, 2
- acute ards respiratory distress syndrome and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- acute ards respiratory distress syndrome and logistic regression model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
- acute ards respiratory distress syndrome and lung infiltrate: 1
- acute ards respiratory distress syndrome and lung percentage: 1, 2, 3, 4, 5
- admission confusion and logistic regression: 1
- admission confusion and logistic regression model: 1
- liver cirrhosis and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- liver cirrhosis and logistic regression model: 1, 2
- liver cirrhosis and lopinavir ritonavir: 1, 2, 3, 4
- liver cirrhosis and lopinavir ritonavir trial: 1
- liver cirrhosis and lung percentage: 1
- logistic regression and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30
- logistic regression and lung infiltrate: 1, 2
- logistic regression and lung percentage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- logistic regression model and lopinavir ritonavir: 1, 2, 3, 4, 5, 6
- logistic regression model and lung percentage: 1
Co phrase search for related documents, hyperlinks ordered by date